Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project

Background and objective: Papillary renal cell carcinoma (pRCC) is a rare disease. The optimal treatment of metastatic pRCC is still unclear. We evaluated real-world treatment outcomes of first-line treatment in this cohort in Germany. Methods: Patients with advanced or metastatic pRCC were eligible...

Full description

Bibliographic Details

Published in:	European Urology Open Science
Main Authors:	Thomas Hilser, Jozefina Casuscelli, Can Aydogdu, Stefanie Zschäbitz, Marco Julius Schnabel, Emily Rinderknecht, Angelika Mattigk, Martin Schostak, Anna-Lisa Volk, Philipp Ivanyi, Jonas Wiegmann, Christopher Darr, Luka Flegar, Subhajit Mandal, Katrin Schlack, Daniel Seidl, Analena Handke, Melanie Klee, Tim Nestler, Marc Rehlinghaus, Sameh Hijazi, Axel Heidenreich, Viktor Grünwald, Pia Paffenholz
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Subjects:	Papillary renal cell cancer Immune checkpoint inhibitor Tyrosine kinase inhibitor First-line treatment
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168325002447